Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Munich, Germany, 81377
- University of Munich - Klinikum Grosshdern
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically proven, metastatic breats cancer.
- HER2-neu overexpression (IHC3+ or IHC2+/FISH+)
- Written informed consent
- no previous therapy with vinorelbine or trastuzumab
- Age * 18 and * 75 years
- Karnofsky-Performance status > 70%
- Life expectance 16 weeks and more
- Availability of at least one target lesion according to RECIST-criteria. Target lesions need to be outside of radiation fields. Bone metastases are excluded as indicator leasions
Exclusion of pregnancy and adequte contraception during childbearing age.
- Adequate hematological, renal, and hepatic function
- Normal cardiac function. LVEF should not be >10% below normal.
- Adequate compliance to perform treatment and subsequent follow-up visits
Exclusion Criteria:
- Locoregional recurrence of breast cancer only or development of contralateral breast cancer
- Pregnancy or lactation
- Symptomatic brain- or meningeal metastasis
- Concurrent endocrine antitumor therapy
- Other malignancies except basal cell cancer of the skin or in-situ carcinoma of the cervix
- Peripheral neuropathy >= NCI CTC Grade 2.
- other severel disease which preclude adequate treatment
- Participation in a clinical trial within the last 30 days.
- Psychological, familial, sociological or geographical conditions which preclude treatment according to the protocol or the planned follow-up
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Response rate
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Overall survival
|
|
Safety
|
|
Time to tumor progression
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Volker Heinemann, PhD, MD, University of Munich - Klinikum Grosshadern
- Study Chair: Hans-Joachim Stemmler, PhD, MD, University of Munich - Klinikum Grosshadern
Study record dates
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Mamma-2-2004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.